Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Zynex Reports First Quarter 2025 Financial Results

      Zynex

      News provided by

      Zynex, Inc.

      Apr 29, 2025, 16:02 ET

      Share this article

      Share this article


      ENGLEWOOD, Colo., April 29, 2025 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today reported its financial and operational results for the first quarter ended March 31, 2025.

      Management Commentary 

      "In the first quarter of 2025, we continued to see steady orders for our pain management and private-labeled rehabilitation products. Total orders decreased 3% year-over-year, but our sales force headcount was approximately 39% less as we continue to focus on sales rep productivity, so we were encouraged by the strong performance of the current sales reps. As we previously announced, we were notified of a temporary suspension of payments from our largest insurance customer, Tricare," said Thomas Sandgaard, President and CEO of Zynex. "We appealed the temporary suspension and had an appeals meeting in April where we presented our data and evidence. We expect a response from Tricare in June or possibly sooner. As directed by Tricare, we continue to support both existing patients and new patients as we receive their prescriptions.

      "We made the difficult decision to decrease our overall staff by approximately 15% in the first quarter, which along with other expense reduction efforts should result in savings of approximately $35 million annually. We continue to monitor expenses and adjust as necessary."

      Mr. Sandgaard concluded: "We expect to complete our FDA submission for our NiCO laser pulse oximeter in the next couple of weeks, which we believe can be a significant driver of new customers, revenue streams and will diversify our product offering.  Overall, we remain optimistic about the growth opportunities both in pain management and patient monitoring."

      First Quarter 2025 Financial Results

      Net revenue was $26.6 million for the three months ended March 31, 2025, compared to $46.5 million in the prior year quarter.

      Gross profit in the quarter ended March 31, 2025, was $18.2 million, or 69% of revenue, as compared to $37.2 million or 80% of revenue, in the first quarter of 2024. Gross profit was affected by the Tricare payment suspension and continuing to support new and existing Tricare patients which yields cost of goods sold with no related revenue.

      Sales and marketing expense for the three months ended March 31, 2025, decreased 28% to $16.9 million from $23.4 million for the same period in 2024, primarily due to decreased headcount in the sales force.

      General and administrative expenses for the three months ended March 31, 2025, were $14.4 million, versus $13.3 million in the prior year period.

      Net loss for the three months ended March 31, 2025, totaled ($10.4) million, or ($0.33) per basic and diluted share, as compared to net income of $10,000, or $0.00 per basic and diluted share, in the quarter ended March 31, 2024.

      Adjusted EBITDA loss for the three months ended March 31, 2025, was ($11.8) million, as compared to Adjusted EBITDA of $1.7 million in the quarter ended March 31, 2024.

      Cash flows from operations for the three months ended March 31, 2025, was ($10.5) million. As of March 31, 2025, the Company had working capital of $40.1 million. Cash and cash equivalents were $23.9 million at March 31, 2025.

      Second Quarter 2025 Guidance

      The Company expects Q2 2025 net revenue of at least $27 million. Loss per share is expected to be ($0.20) per share or better. The Company expects quarterly revenues to increase throughout the year with the usual seasonality typically experienced.

      Conference Call and Webcast Details
      Date: Tuesday, April 29, 2025
      Time: 4:15 PM Eastern Time (2:15 PM Mountain Time)
      U.S. & Canada dial-in number: 800-836-8184
      International number: 646-357-8785
      Webcast: 1Q25 Webcast Link

      Non-GAAP Financial Measures

      Zynex reports its financial results in accordance with accounting principles generally accepted in the U.S. (GAAP). In addition, the Company is providing in this news release financial information in the form of Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization, other income/expense, stock compensation, restructuring, receivables adjustment and non-cash lease charges). Management believes these non-GAAP financial measures are useful to investors and lenders in evaluating the overall financial health of the Company in that they allow for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from, or as an alternative to, the financial information prepared in accordance with GAAP.

      Safe Harbor Statement

      This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. our results of operations and the plans, strategies and objectives for future operations; the timing and scope of any potential stock repurchase; and other similar statements.

      Words such as "anticipate," "believe," "continue," "could," "designed," "endeavor," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "seek," "should," "target," "preliminary," "will," "would" and similar expressions are intended to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain CE marking of new products; the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources; the need to keep pace with technological changes; our dependence on the reimbursement for our products from health insurance companies; our dependence on first party manufacturers to produce our products on time and to our specifications' implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy; market conditions; the timing, scope and possibility that the repurchase program may be suspended or discontinued; economic factors, such as interest rate fluctuations; and other risks described in our filings with the Securities and Exchange Commission.

      These and other risks are described in our filings with the Securities and Exchange Commission including but not limited to, our Annual Report on Form 10-K for the year ended December 31, 2024, as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statements contained in this press release represent Zynex's views only as of today and should not be relied upon as representing its views as of any subsequent date. Zynex explicitly disclaims any obligation to update any forward-looking statements, except to the extent required by law.

      About Zynex, Inc.

      Zynex, founded in 1996, develops, manufactures, markets, and sells medical devices used for pain management and rehabilitation as well as non-invasive fluid, sepsis, and laser-based pulse oximetry monitoring systems for use in hospitals. For additional information, please visit: www.zynex.com.

      Investor Relations Contact:
      Brian M. Prenoveau, CFA
      MZ Group – MZ North America
      [email protected]
      +561 489 5315

      ZYNEX, INC.

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (AMOUNTS IN THOUSANDS)

      (unaudited)



      March 31,


      December 31,



      2025


      2024

      ASSETS







      Current assets:







      Cash and cash equivalents


      $

      23,852


      $

      39,631

      Accounts receivable, net



      14,053



      18,022

      Inventory, net



      13,531



      13,919

      Prepaid expenses and other



      4,978



      3,607

      Total current assets



      56,414



      75,179








      Property and equipment, net



      3,037



      3,084

      Operating lease asset



      9,118



      9,820

      Finance lease asset



      1,068



      1,141

      Deposits



      408



      408

      Intangible assets, net of accumulated amortization



      7,023



      7,247

      Goodwill



      20,401



      20,401

      Deferred income taxes



      8,290



      4,799

      Total assets


      $

      105,759


      $

      122,079








      LIABILITIES AND STOCKHOLDERS' EQUITY







      Current liabilities:







      Accounts payable and accrued expenses


      $

      8,166


      $

      7,091

      Operating lease liability



      4,081



      4,030

      Finance lease liability



      291



      287

      Accrued payroll and related taxes



      3,779



      5,456

      Total current liabilities



      16,317



      16,864

      Long-term liabilities:







      Convertible senior notes, less issuance costs



      58,818



      58,567

      Operating lease liability



      9,103



      10,151

      Finance lease liability



      747



      789

      Total liabilities



      84,985



      86,371








      Stockholders' equity:







      Common stock



      30



      32

      Additional paid-in capital



      93,489



      93,088

      Treasury stock, at cost



      (92,123)



      (87,186)

      Retained earnings



      19,378



      29,774

      Total stockholders' equity



      20,774



      35,708

      Total liabilities and stockholders' equity


      $

      105,759


      $

      122,079

      ZYNEX, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

      (AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)

      (unaudited)



      For the Three Months Ended March 31, 



      2025


      2024

      NET REVENUE







      Devices


      $

      11,898


      $

      14,025

      Supplies



      14,680



      32,506

      Total net revenue



      26,578



      46,531








      COSTS OF REVENUE AND OPERATING EXPENSES







      Costs of revenue - devices and supplies



      8,369



      9,298

      Sales and marketing



      16,940



      23,380

      General and administrative



      14,366



      13,328

      Total costs of revenue and operating expenses



      39,675



      46,006








      Income (loss) from operations



      (13,097)



      525








      Other expense







      Interest expense, net



      (703)



      (512)

      Other expense, net



      (703)



      (512)








      Income (loss) from operations before income taxes



      (13,800)



      13

      Income tax expense (benefit)



      (3,404)



      3

      Net income (loss)


      $

      (10,396)


      $

      10








      Net income (loss) per share:







      Basic


      $

      (0.33)


      $

      0.00

      Diluted


      $

      (0.33)


      $

      0.00








      Weighted average basic shares outstanding



      31,604



      32,344

      Weighted average diluted shares outstanding



      31,604



      32,827

      ZYNEX, INC.

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (AMOUNTS IN THOUSANDS)

      (unaudited)










      For the Three Months Ended March 31, 



      2025


      2024

      CASH FLOWS FROM OPERATING ACTIVITIES:







      Net income (loss)


      $

      (10,396)


      $

      10

      Adjustments to reconcile net income (loss) to net cash (used in) provided by  operating activities:







      Depreciation



      618



      638

      Amortization



      478



      461

      Stock-based compensation



      577



      734

      Non-cash lease expense



      (296)



      (187)

      Benefit for deferred income taxes



      (3,491)



      (1)

      Change in operating assets and liabilities:







      Accounts receivable



      3,970



      1,399

      Prepaid and other assets



      (510)



      (813)

      Accounts payable and other accrued expenses



      (1,518)



      2,709

      Inventory



      65



      (2,882)

      Net cash (used in) provided by  operating activities



      (10,503)



      2,068








      CASH FLOWS FROM INVESTING ACTIVITIES:







      Purchase of property and equipment



      (168)



      (153)

      Net cash used in investing activities



      (168)



      (153)








      CASH FLOWS FROM FINANCING ACTIVITIES:







      Payments on finance lease obligations



      (39)



      (123)

      Cash dividends paid



      —



      (3)

      Purchase of treasury stock



      (4,939)



      (13,280)

      Proceeds from the issuance of common stock on stock-based awards



      7



      13

      Taxes withheld and paid on employees' equity awards



      (137)



      (240)

      Net cash used in financing activities



      (5,108)



      (13,633)








      Net decrease in cash



      (15,779)



      (11,718)

      Cash and cash equivalents at beginning of period



      39,631



      44,579

      Cash and cash equivalents at end of period


      $

      23,852


      $

      32,861

      ZYNEX, INC.

      RECONCILIATION OF GAAP TO NON-GAAP MEASURES

      (AMOUNTS IN THOUSANDS)

      (unaudited)



      For the Three Months Ended March 31, 




      2025


      2024


      Adjusted EBITDA:








      Net income (loss)


      $

      (10,396)


      $

      10


      Depreciation and Amortization*



      509



      426


      Stock-based compensation expense



      577



      734


      Interest expense and other, net



      703



      512


      Income tax (benefit) expense



      (3,404)



      3


      Restructuring charges**



      227



      —


      Adjusted EBITDA


      $

      (11,783)


      $

      1,685


      % of Net Revenue



      (44)

      %


      4

      %


      * Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold.

      ** Severance of former corporate employees which were fully expensed in Q1-2025.

      SOURCE Zynex, Inc.

      Modal title

      Also from this source

      Zynex Poised for New Future with Resolution of Federal Investigation

      Zynex Poised for New Future with Resolution of Federal Investigation

      Zynex, Inc., today announced that it has resolved the federal government's investigation into business practices designed and implemented by the...

      Zynex Announces New In-Network Provider Status with Humana

      Zynex, Inc. (ZYXIQ), an innovative medical device company specializing in non-invasive medical devices for pain management, announced it has for the...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Medical Equipment

      Medical Equipment

      Earnings

      Earnings

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.